Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Zhejiang Hisun Pharmaceutical Co., Ltd.
483
•Zhejiang Hisun Pharmaceutical Co., Ltd.•August 11, 2017

Zhejiang Hisun Pharmaceutical Co., Ltd. – FDA 483, Aug 11, 2017

Record Details

An FDA inspection conducted from August 7 to 11, 2017, at Zhejiang Hisun Pharmaceutical Co., Ltd. in Taizhou, Zhejiang, China, identified multiple significant observations for the API/Finished Drug Product Manufacturer. The findings, detailed in an FDA 483 report, indicate areas where the company's practices deviated from regulatory expectations for quality manufacturing.

Key issues included concerns about laboratory data integrity, with incomplete records, missing audit trails for stability data, and insufficient controls for stand-alone analytical systems. Equipment cleaning and maintenance procedures were deemed deficient, lacking scientific justification for sampling points and specific instructions. The facility also failed to appropriately monitor storage conditions for stability samples, and records were not completed contemporaneously. Further observations highlighted incomplete data in microbial limit testing records, insufficient documentation for manufacturing process changes without risk assessments, and a lack of complete historical data in process validation studies. Additionally, the final API storage areas were found to be in disrepair, with observed water leakage. The company is required to thoroughly address these observations by implementing robust corrective and preventive actions to ensure compliance.

Company
Zhejiang Hisun Pharmaceutical Co., Ltd.
Inspection date
August 11, 2017
Office
Office of Scientific Investigations
People
  • Peter E. Baker (President)
  • Parul M. Patel (investigator)
View Company Profile

ID · 79173a11-bcaa-4b81-8e6b-2662fd1b9d1a

Violation Codes3
21 CFR 21021 CFR 21121 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 483 - 2019-06-07June 7, 2019
  • 483 - 2017-08-07August 7, 2017
  • 483 - 2017-01-19January 19, 2017
  • 483 - 2017-01-16January 16, 2017
  • WARNING_LETTER - 2015-03-07March 7, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Hisun Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.